Biopharmaceutical formulations for pre-filled delivery devices

Expert Opinion on Drug Delivery

Volumn 10, Issue 6, 2013, Pages 811-828

  Jezek, Jan ^a   Darton, Nicholas J ^a   Derham, Barry K ^a   Royle, Nikki ^a   Simpson, Iain ^b  

^a Arecor Limited   (United Kingdom)

^b Cambridge Consultants Limited   (United Kingdom)

Author keywords

Aggregation; Antibodies; Autoinjectors; Biologics; Biopharmaceuticals; Deamidation; Formulation; Olefins; Oxidation; PFS; Polymers; Pre filled; Protein degradation; Silicone oil; Syringes; Tungsten; Vaccines; Viscosity

Indexed keywords

ANTIOXIDANT; ASPARTIC ACID; BUFFER; GLASS; ISOASPARTIC ACID; PLASTIC; POLYMER; PRESERVATIVE; PROTEIN; SILICONE OIL; STABILIZING AGENT; SUCCINIMIDE; SURFACTANT; TUNGSTEN;

DEAMINATION; DIAFILTRATION; DRUG DELIVERY DEVICE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; FRAGMENTATION REACTION; HUMAN; ISOMERIZATION; LIQUID; OXIDATION; PH; PREFILLED DELIVERY DEVICE; REVIEW; STRESS; SYRINGE; ULTRAFILTRATION; VISCOSITY;

ANIMALS; BIOLOGICAL AGENTS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG PACKAGING; DRUG STABILITY; EXCIPIENTS; HUMANS; SYRINGES;

EID: 84878090788     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.780023     Document Type: Review

References (148)

1. Berteau C, Schwarzenbach F, Donazzolo Y, et al. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence 2010;4:379-88
2. Harrison B, Rios M. Developments in pre-filled syringes. Pharm Techol 2007;31(3):50-60
3. Overcashier D, Chan E, Hsu C. Technical considerations in the development of pre-filled syringes for protein products. Am Pharm Rev 2006;9:77-82
4. Visiongain. Pre-Filled Syringes: World Market Prospects 2012-2022, in press
5. Vaczek D. Promoting dosing accuracy with prefilled syringes. Pharm Med Pack News 2007;15:42-50
6. Kiang P. Future materials for pre-filled syringe components. Am Pharm Rev 2011;14:54-8
7. Sacha GA, Saffell-Clemmer W, Abram K, et al. Practical fundamentals of glass, rubber, and plastic sterile packaging systems. Pharm Dev Technol 2010;15:6-34
8. Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res 2010;27:544-75
9. Osterberg RE, Demerlis CC, Hobson DW, et al. Trends in excipient safety evaluation. Int J Toxicol 2011;30:600-10
10. FDA Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients 2005
11. Jorgensen L, Hostrup S, Moeller EH, et al. Recent trends in stabilising peptides and proteins in pharmaceutical formulation -considerations in the choice of excipients. Expert Opin Drug Deliv 2009;6:1219-30
12. Haaland P. Experimental design in biotechnology. Marcel Dekker, New York; 1989
13. Rader R. Biopharmaceutical products in the US and European markets. 6th edition. Bioplan Associates, Inc, Rockville, MD; 2007
14. Sek D. Breaking old habits: moving away from commonly used buffers in pharmaceuticals. Eur Pharm Rev 2012;7:37-41
15. Beynon R, Easterby JS. Buffer solutions: The basics. IRL Press, Taylor & Francis, UK; 1996
16. Jezek J. The stabilization of proteins. WO2008084237A2; 2008
17. Kennedy DM, Skillen AW, Self CH. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin Exp Immunol 1994;98:245-51
18. Zhang Y, Cremer PS. Interactions between macromolecules and ions: the Hofmeister series. Curr Opin Chem Biol 2006;10:658-63
19. Nema S, Washkuhn RJ, Brendel RJ. Excipients and their use in injectable products. PDA J Pharm Sci Technol 1997;51:166-71
20. Randolph TW, Jones LS. Surfactant-protein interactions. Pharm Biotechnol 2002;13:159-75
21. Bam NB, Cleland JL, Yang J, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci 1998;87:1554-9
22. Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 1996;85:1325-30
23. Mollmann SH, Elofsson U, Bukrinsky JT, et al. Displacement of adsorbed insulin by Tween 80 monitored using total internal reflection fluorescence and ellipsometry. Pharm Res 2005;22:1931-41
24. Thurow H, Geisen K. Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces. Diabetologia 1984;27:212-18
25. Kreilgaard L, Jones LS, Randolph TW, et al. Effect of Tween 20 on freezethawing-and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 1998;87:1597-603
26. Kiese S, Papppenberger A, Friess W, et al. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 2008;97:4347-66
27. Timasheff SN. Protein-solvent preferential interactions, protein hydration, and the modulation of biochemical reactions by solvent components. Proc Nat Acad Sci USA 2002;99:9721-6
28. Kishore RSK, Pappenberger A, Dauphin IB, et al. Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis. J Pharm Sci 2011;100:721-31
29. Hutchings RL, M Singh S, Cabello-Villegas J, et al. Effect of antimicrobial preservatives on partial protein unfolding and aggregation. J Pharm Sci 2012;102(2):365-76
30. Jezek J, Derham BK. Protein formulations. WO2011104557A1; 2011
31. Pharmacopeia U. United States Pharmacopeia general chapter. Antimicrobial effectiveness testing
32. Grillo AO, Edwards KL, Kashi RS, et al. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry 2001;40:586-95
33. Pretzer D, Schulteis B, Vander Velde DG, et al. Effect of zinc binding on the structure and stability of fibrolase, a fibrinolytic protein from snake venom. Pharm Res 1992;9:870-7
34. Khossravi M, Borchardt RT. Chemical pathways of peptide degradation. X: effect of metal-catalyzed oxidation on the solution structure of a histidine-containing peptide fragment of human relaxin. Pharm Res 2000;17:851-8
35. Yang TH, Cleland JL, Lam X, et al. Effect of zinc binding and precipitation on structures of recombinant human growth hormone and nerve growth factor. J Pharm Sci 2000;89:1480-5
36. Jezek J. Protein formulation. WO2009133200A1; 2009
37. Giger K, Vanam RP, Seyrek E, et al. Suppression of insulin aggregation by heparin. Biomacromolecules 2008;9:2338-44
38. Fedunova D, Antal?k M. Prevention of thermal induced aggregation of cytochrome c at isoelectric pH values by polyanions. Biotechnol Bioeng 2006;93:485-93
39. Jezek J, Derham BK, Zapadka K. Stabilized aqueous antibody compositions. WO2012013980; 2006
40. Otzen DE, Knudsen BR, Aachmann F, et al. Structural basis for cyclodextrins' suppression of human growth hormone aggregation. Protein Sci 2002;11:1779-87
41. Tavornvipas S, Tajiri S, Hirayama F, et al. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res 2004;21:2369-76
42. Jezek J, Derham BK. Stable formulation of Factor VIII. WO2011027152A1; 2009
43. Baynes BM, Trout BL. Rational design of solution additives for the prevention of protein aggregation. Biophys J 2004;87:1631-9
44. Schneider CP, Trout BL. Investigation of cosolute-protein preferential interaction coefficients: new insight into the mechanism by which arginine inhibits aggregation. J Phys Chem B 2009;113:2050-8
45. Morefield GL, HogenEsch H, Robinson JP, et al. Distribution of adsorbed antigen in mono-valent and combination vaccines. Vaccine 2004;22:1973-84
46. Martinez T, Guo A, Allen MJ, et al. Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 2008;47:7496-508
47. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005;289:1-30
48. Chi EY, Krishnan S, Randolph TW, et al. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003;20:1325-36
49. Mahler H-C, Friess W, Grauschopf U, et al. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009;98:2909-34
50. Wang W, Kelner DN. Correlation of rFVIII inactivation with aggregation in solution. Pharm Res 2003;20:693-700
51. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 2003;61:S11-12
52. Carpenter JF, Randolph TW, Jiskoot W, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 2009;98:1201-5
53. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006;8:E501-7
54. Trevino SR, Scholtz JM, Pace CN. Measuring and increasing protein solubility. J Pharm Sci 2008;97:4155-66
55. Narhi LO, Schmit J, Bechtold-Peters K, et al. Classification of protein aggregates. J Pharm Sci 2012;101:493-8
56. Demeule B, Messick S, Shire SJ, et al. Characterization of particles in protein solutions: reaching the limits of current technologies. AAPS J 2010;12:708-15
57. Singh SK, Afonina N, Awwad M, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 2010;99:3302-21
58. Das TK. Protein particulate detection issues in biotherapeutics development-current status. AAPS PharmSciTech 2012;13:732-46
59. Sharma B, Bader F, Templeman T, et al. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex. Eur J Hosp Pharm Pract 2004;5:86-91
60. Huang C-T, Sharma D, Oma P, et al. Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 2009;98:3058-71
61. Sharma D, Oma P, Krishnan S. Silicone microdroplets in protein formulations. Pharma Tech 2009;33:74-9
62. Simler BR, Hui G, Dahl JE, et al. Mechanistic complexity of subvisible particle formation: links to protein aggregation are highly specific. J Pharm Sci 2012;101:4140-54
63. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004;93:1390-402
64. Wakankar AA, Borchardt RT. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 2006;95:2321-36
65. Patel K, Borchardt RT. Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm Res 1990;7:787-93
66. Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res 1993;10:95-102
67. Gietz U, Alder R, Langguth P, et al. Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: effect of pH. Pharm Res 1998;15:1456-62
68. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 1987;262:785-94
69. Tyler-Cross R, Schirch V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem 1991;266:22549-56
70. Hepner F, Csaszar E, Roitinger E, et al. Massspectrometrical analysis of recombinant human growth hormone Norditropin reveals amino acid exchange at M14V14 rhGH. Proteomics 2006;6:775-84
71. Joshi AB, Sawai M, Kearney WR, et al. Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. J Pharm Sci 2005;94:1912-27
72. Zhang W, Czupryn JMJ, Boyle PT, et al. Characterization of asparagine deamidation and aspartate isomerization in recombinant human interleukin-11. Pharm Res 2002;19:1223-31
73. Ribot WJ, Powell BS, Ivins BE, et al. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine 2006;24:3469-76
74. Harris RJ, Kabakoff B, Macchi FD, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 2001;752:233-45
75. Xiao G, Bondarenko P V. Identification and quantification of degradations in the Asp-Asp motifs of a recombinant monoclonal antibody. J Pharm Biomed Anal 2008;47:23-30
76. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203:1-60
77. Li R, Hageman MJ, Topp EM. Effect of viscosity on the deamidation rate of a model Asn-hexapeptide. J Pept Res 2002;59:211-20
78. Clarke S. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int J Pept Protein Res 1987;30:808-21
79. Kaisheva E, Gupta S, Flores-Nate A. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization. WO2004039337; 2004
80. Zheng JY, Janis LJ. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int J Pharm 2006;308:46-51
81. Girardet J-M, N'negue M-A, Egito AS, et al. Multiple forms of equine alphalactalbumin: evidence for N-glycosylated and deamidated forms. Int Dairy J 2004;14:207-17
82. Liu H, Gaza-Bulseco G, Sun J. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci 2006;837:35-43
83. Jiskoot W, Beuvery EC, De Koning AA, et al. Analytical approaches to the study of monoclonal antibody stability. Pharm Res 1990;7:1234-41
84. Ouellette D, Alessandri L, Piparia R, et al. Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine. Anal Biochem 2009;389:107-17
85. Hovorka S, Schoneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J Pharm Sci 2001;90:253-69
86. Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta 2005;1703:93-109
87. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993;10:307-77
88. Stadtman ER. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 1993;62:797-821
89. Agon V V, Bubb WA, Wright A, et al. Sensitizer-mediated photooxidation of histidine residues: evidence for the formation of reactive side-chain peroxides. Free Radical Biol Med 2006;40:698-710
90. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999;185:129-88
91. Li S, Schoneich C, Borchardt RT. Chemical pathways of peptide degradation. VIII. Oxidation of methionine in small model peptides by prooxidant/transition metal ion systems: influence of selective scavengers for reactive oxygen intermediates. Pharm Res 1995;12:348-55
92. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 2006;58:686-706
93. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res 1989;6:903-18
94. Tashjian AH, Ontjes DA, Munson PL. Alkylation and oxidation of methionine in bovine parathyroid hormone: effects on hormonal activity and antigenicity. Biochemistry 1964;3:1175-82
95. Schenck HL, Dado GP, Gellman SH. Redox-triggered secondary structure changes in the aggregated states of a designed methionine-rich peptide. J Am Chem Soc 1996;118:12487-94
96. Liu D, Ren D, Huang H, et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 2008;47:5088-100
97. Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 2002;91:2252-64
98. Yokota H, Saito H, Masuoka K, et al. Reversed phase HPLC of Met58 oxidized rhIL-11: oxidation enhanced by plastic tubes. J Pharm Biomed Anal 2000;24:317-24
99. Ji JA, Zhang B, Cheng W, et al. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization. J Pharm Sci 2009;98:4485-500
100. Dalsgaard TK, Otzen D, Nielsen JH, et al. Changes in structures of milk proteins upon photo-oxidation. J Agric Food Chem 2007;55:10968-76
101. Kerwin BA, Remmele RL. Protect from light: photodegradation and protein biologics. J Pharm Sci 2007;96:1468-79
102. FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics
103. Wakankar AA, Wang YJ, Canova-Davis E, et al. On developing a process for conducting extractable-leachable assessment of components used for storage of biopharmaceuticals. J Pharm Sci 2010;99:2209-18
104. Jenke D. Evaluation of the chemical compatibility of plastic contact materials and pharmaceutical products; safety considerations related to extractables and leachables. J Pharm Sci 2007;96:2566-81
105. Adler M. Challenges in the development of pre-filled syringes for biologics from a formulation scientist's point of view. Am Pharm Rev 2012;15:1-8
106. Smith EJ. Siliconization of parentral drug packaging components. J Parent Sci Technol 1988;42:S3-S13
107. Romacker MTS, Forster R. The rise of prefilled syringes from niche product to primary container of choice: a short history. ONdrug Delivery 2008;4:4-5
108. Badkar A, Wolf A, Bohack L, et al. Development of biotechnology products in pre-filled syringes: technical considerations and approaches. AAPS PharmSciTech 2011;12:564-72
109. Felsovalyi F, Janvier S, Jouffray S, et al. Silicone-oil-based subvisible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals. J Pharm Sci 2012;101:4569-83
110. Baldwin RN. Contamination of insulin by silicone oil: a potential hazard of plastic insulin syringes. Diabet Med 1988;5:789-90
111. Chantelau E, Berger M, Bohlken B. Silicone oil released from disposable insulin syringes. Diabetes Care 1986;9:672-3
112. Chantelau EA, Berger M. Pollution of insulin with silicone oil, a hazard of disposable plastic syringes. Lancet 1985;1:1459
113. Thirumangalathu R, Krishnan S, Ricci MS, et al. Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 2009;98:3167-81
114. Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci 2005;94:918-27
115. Majumdar S, Ford BM, Mar KD, et al. Evaluation of the effect of syringe surfaces on protein formulations. J Pharm Sci 2011;100:2563-73
116. United States Pharmacopeia general chapter Particulate Matter in Injections
117. Ludwig DB, Carpenter JF, Hamel J-B, et al. Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions. J Pharm Sci 2010;99:1721-33
118. Lubiniecki A, Volkin DB, Federici M, et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 2011;39:9-22
119. Sluzky V, Tamada JA, Klibanov AM, et al. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Nat Acad Sci USA 1991;88:9377-81
120. Bee JS, Nelson SA, Freund E, et al. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci 2009;98:3290-301
121. Jiang Y, Nashed-Samuel Y, Li C, et al. Tungsten-induced protein aggregation: solution behavior. J Pharm Sci 2009;98:4695-710
122. Waxman L, Steeley T, Vilivalam V. Protein sensitivity to tungsten. Pharma Tech 2011;28-32
123. Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 2012;29:1454-67
124. Bee JS, Stevenson JL, Mehta B, et al. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng 2009;103:936-43
125. Sacha GA, Saffell-Clemmer W, Abram K, et al. Practical fundamentals of glass, rubber, and plastic sterile packaging systems. Pharm Dev Technol 2010;15:6-34
126. Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol 2009;20:708-14
127. Burckbuchler V, Mekhloufi G, Giteau AP, et al. Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions. Eur J Pharm Biopharma 2010;76:351-6
128. Jezek J, Rides M, Derham B, et al. Viscosity of concentrated therapeutic protein compositions. Adv Drug Deliv Rev 2011;63:1107-17
129. Saluja A, Kalonia DS. Nature and consequences of protein-protein interactions in high protein concentration solutions. Int J Pharm 2008;358:1-15
130. Curtis R, Prausnitz J, Blanch H. Protein-protein and protein-salt interactions in aqueous protein solutions containing concentrated electrolytes. Biotechnol Bioeng 1998;57:11-21
131. Liu J, Nguyen MDH, Andya JD, et al. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 2005;94:1928-40
132. Saluja A, Kalonia DS. Application of ultrasonic shear rheometer to characterize rheological properties of high protein concentration solutions at microliter volume. J Pharm Sci 2005;94:1161-8
133. Rathore N, Pranay P, Bernacki J, et al. Characterization of protein rheology and delivery forces for combination products. J Pharm Sci 2012;101(12):4472-80
134. Liu J, Shire S. High concentration antibody and protein formulations. US20040197324 A1; 2012
135. Liu J, Shire S. Methods of treating IgE-mediated disorders comprising the administration of high concentration Anti-IgE antibody formulations. US20050158303 A1; 2010
136. Liu J, Shire S. Method of reducing viscosity of high concentration protein formulations. US7666413 B2; 2010
137. Morichika T, Kameoka D, Imaeda Y, et al. High concentration antibody-containing liquid formulation. EP2238985A1; 2010
138. Osslund T. High concentration antibody formulations. WO2011143307A1; 2011
139. Chen T. Concentrated protein formulations and uses thereof. WO2011109365A2; 2011
140. He F, Woods CE, Litowski JR, et al. Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions. Pharm Res 2011;28:1552-60
141. Bowen M, Armstrong N, Maa Y. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J Pharm Sci 2012;101:4433-43
142. Hill B, Dai W. Non-aquous high concentration reduced viscosity suspension formulations. US 20110223208 A1; 2011
143. Johnston K, Mazuski M, Engstrom J, et al. Low Viscosity Highly Concentrated Suspensions. WO 2010056657 A2; 2010
144. He F, Woods CE, Trilisky E, et al. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J Pharm Sci 2010;100:1330-40
145. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114:230-41
146. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012;13:869-78
147. Adler M, Grauschopf U, Mahler H-C, et al. Subcutaneous anti-HER2 antibody formulations and uses thereof. US 20110044977 A1; 2011
148. Rosenfeld CR, Bohannon NJ, Bode B, et al. TheV-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control. Endocr Pract 2012;18:660-7